Coldstream Capital Management Inc. Has $305,000 Stake in Masimo Co. (NASDAQ:MASI)

Coldstream Capital Management Inc. reduced its position in Masimo Co. (NASDAQ:MASI) by 6.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,281 shares of the medical equipment provider’s stock after selling 169 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Masimo were worth $305,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of MASI. Geode Capital Management LLC lifted its holdings in shares of Masimo by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock worth $105,741,000 after acquiring an additional 11,984 shares during the period. Barclays PLC lifted its stake in Masimo by 152.6% during the third quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider’s stock worth $5,329,000 after purchasing an additional 24,137 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Masimo during the third quarter valued at approximately $519,000. MML Investors Services LLC grew its stake in shares of Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 96 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Masimo in the 3rd quarter worth approximately $2,288,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

MASI has been the topic of several recent analyst reports. Wells Fargo & Company boosted their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler increased their target price on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a research report on Wednesday, November 6th. Finally, BTIG Research raised their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Masimo Stock Performance

Masimo stock opened at $176.14 on Monday. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $178.87. The stock has a 50-day simple moving average of $157.26 and a 200 day simple moving average of $133.23. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $9.43 billion, a price-to-earnings ratio of 121.48 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same period in the previous year, the firm posted $0.63 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. On average, research analysts anticipate that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.